Details for New Drug Application (NDA): 020593
✉ Email this page to a colleague
NDA 020593 describes DEPACON, which is a drug marketed by Abbvie and is included in one NDA. Additional details are available on the DEPACON profile page.
The generic ingredient in DEPACON is valproate sodium. There are nine drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the valproate sodium profile page.
The generic ingredient in DEPACON is valproate sodium. There are nine drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the valproate sodium profile page.
Summary for 020593
| Tradename: | DEPACON |
| Applicant: | Abbvie |
| Ingredient: | valproate sodium |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 100MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Dec 30, 1996 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
